Ergotrate Maleate Side Effects
Generic name: ergonovine
Medically reviewed by Drugs.com. Last updated on Aug 19, 2022.
Note: This document contains side effect information about ergonovine. Some dosage forms listed on this page may not apply to the brand name Ergotrate Maleate.
Applies to ergonovine: compounding powder, injectable solution, oral tablet.
Administration of correct dose to carefully selected patients who are closely monitored, yields little risk of serious adverse systemic effects; however, IV administration may produce serious adverse effects if the injections are not diluted and administered slowly.[Ref]
Frequency not reported: Gangrene, coronary artery vasospasm, peripheral vasospasm, hypotension, hypertension, thrombophlebitis, myocardial infarction (single case report), ventricular arrhythmias, transient chest pain, palpitation, bradycardia, vasoconstriction
Very rare (less than 0.01%): Mesenteric ischemia and large bowel infarction (single case report)
Frequency not reported: Allergic phenomena (including shock, hypertension, chest pain, palpitation, dyspnea, and bradycardia), anaphylactic/anaphylactoid reaction
Frequency not reported: Clinical exacerbations of porphyria, water intoxication
Frequency not reported: Sweating, diaphoresis, skin rashes
Very rare (less than 0.01%): Unmasking of myasthenia gravis (single case report)
Frequency not reported: Leg cramps
Postmarketing reports: Muscle spasm
Postmarketing reports: Eye movement disorder
Frequency not reported: Hallucinations
Frequency not reported: Hematuria
Frequency not reported: Abnormal liver function test
Postmarketing reports: Increased blood creatine
More about Ergotrate Maleate (ergonovine)
Related treatment guides
1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
2. Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.